Consortium Member of the Month
Our consortium member of the month for the month of May goes to Gina Bellenger from Moffitt Cancer Center!
Gina Bellenger
Clinical Research Coordinator Associate
Gina Bellenger has been actively involved in sample collection for an MPN research study since 2021 and has been integral to its enrollment and ongoing maintenance. Gina’s hard work has played a significant role in the contribution of Moffitt Cancer Center to the consortium. She constantly works with the PI and investigators at Moffitt.
Nominated by: Victoria Rivera
Gina, thank you so much for all of the phenomenal work you have done for the consortium.
Keep up the great work!
MPN-RC Monthly Publication
Title: Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis
Author(s): Marina Kremyanskaya, Yelena Z. Ginzburg, and Ronald Hoffman
ASH Conference 2025
ASH Abstracts
-
Marina Kremyanskaya, MD,PhD
Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

-
John Crispino, PhD,MBA
Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

-
John Mascarenhas, MD
Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

-
Andrew Kuykendall, MD
A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

-
Min Lu, MD,PhD
Myelofibrosis stem cell fitness requires microenvironmental cell interactions

-
Xiaoli Wang, MD,PhD
Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

-
MD Babu Mia, PhD
Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

